Eliza A. Hawkes

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

David Cunningham, Eliza A. Hawkes, Andrew Jack et al. · The Lancet · 2013 · 556 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi

Francesco Merli, Stefano Luminari, Alessandra Tucci et al. · Journal of Clinical Oncology · 2021 · 160 citations · Full text

Medicine, Geriatric Medicine, Oncology +15

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

Maher K. Gandhi, Thanh Hoang, Soi Cheng Law et al. · Blood · 2020 · 119 citations · Full text

Medicine, Immunology, Oncology +12

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,<i>KRAS</i>Wild-Type, Metastatic Colorectal Cancer

Francesco Sclafani, Tae‐Yop Kim, David Cunningham et al. · JNCI Journal of the National Cancer Institute · 2015 · 90 citations · Full text

Medicine, Oncology, Pharmacology +12

Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial

Mary Gleeson, Nicholas Counsell, David Cunningham et al. · Annals of Oncology · 2017 · 90 citations · Full text

Medicine, Oncology, Pharmacotherapy +16